Cargando…
Comparing outcomes between neoadjuvant hormonal therapy followed by prostatectomy versus upfront prostatectomy in high-risk prostate cancer: The road ahead
Autor principal: | Bhargava, Priyank |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10249518/ https://www.ncbi.nlm.nih.gov/pubmed/37304992 http://dx.doi.org/10.4103/iju.iju_409_22 |
Ejemplares similares
-
Adjuvant intravesical chemohyperthermia or conventional chemotherapy in an era of bacillus Calmette-Guérin shortage for non-muscle invasive bladder cancer: The HIVEC-II trial
por: Bhargava, Priyank
Publicado: (2023) -
Can early salvage radiotherapy replace adjuvant radiotherapy as the new standard of care for high-risk postradical prostatectomy patients?
por: Pandey, Abhishek
Publicado: (2021) -
TITAN trial; shifting focus from hormone-refractory to hormone-sensitive prostate cancer
por: Kumar, Gautam
Publicado: (2020) -
Docetaxel, abiraterone, enzalutamide, apalutamide in patients with metastatic hormone-sensitive prostate cancer
por: Talwar, Harkirat Singh
Publicado: (2021) -
A game changing LATITUDE: Role of abiraterone plus prednisolone in metastatic hormone-sensitive prostate cancer
por: Sharma, Aditya Prakash
Publicado: (2017)